Patient characteristics at the PATENT-1 study baseline
| Characteristic | Former riociguat 2.5 mg maximum | Former riociguat 1.5 mg maximum | Former placebo | Total |
| Patients n | 231 | 56 | 109 | 396 |
| Age years | 50±16 | 48±16 | 49±16 | 50±16 |
| Female | 186 (81) | 44 (79) | 87 (80) | 317 (80) |
| Treatment naïve | 114 (49) | 30 (54) | 53 (49) | 197 (50) |
| Pretreated | 117 (51) | 26 (46) | 56 (51) | 199 (50) |
| PAH classification | ||||
| Idiopathic | 136 (59) | 35 (63) | 74 (68) | 245 (62) |
| Familial | 7 (3) | 1 (2) | 1 (1) | 9 (2) |
| Connective tissue disease-associated PAH | 63 (27) | 13 (23) | 18 (17) | 94 (24) |
| Congenital heart disease-associated PAH | 14 (6) | 7 (13) | 12 (11) | 33 (8) |
| Portal PH | 10 (4) | 0 | 2 (2) | 12 (3) |
| Anorexigen/amphetamine-associated PAH | 1 (0.4) | 0 | 2 (2) | 3 (1) |
| 6MWD m | 364±67 | 359±68 | 378±66 | 367±67 |
| WHO functional class | ||||
| I–IV patients n | 231 | 56 | 108 | 395 |
| I/II/III/IV | 2/42/55/0# | 7/30/63/0# | 3/50/45/2 | 3/43/54/1# |
| 100 | 101# |
Data are presented as mean±sd, n (%) or %, unless otherwise stated. PAH: pulmonary arterial hypertension; PH: pulmonary hypertension; 6MWD: 6-min walking distance; WHO: World Health Organization. #: data does not add up to 100% due to rounding.